Preliminary Study of the Effect of FK506 Nanospheric-Suspension Eye Drops on Rejection of Penetrating Keratoplasty
The aim of this study was to investigate the effect of a topical FK506 nanospheric suspension in a rat model of penetrating keratoplasty.
FK506 nanospheres were prepared by using a biodegradable poly (lactic-co-glycolic acid) copolymer (PLGA). Its distribution in the eye and blood after a single instillation was examined in rabbits. Sprague-Dawley (SD) rats received corneal heterografts and were topically treated with phosphate-buffered saline (PBS), PLGA, FK-506 0.01% (nanospheres), or dexamethasone 0.05% solutions twice a day for 28 days. Rejection index and graft-survival time were recorded and compared between the four groups. Three grafts were collected at different time points for immunohistochemical studies.
In the cornea, the FK-506 concentration reached its peak within 1 h of a single eye-drop instillation and then decreased by half (1667.85 +/- 611.87 ng/g) at 8 h. FK-506 cannot be detected in rabbit blood. There were significant differences in the graft-survival time between the FK-506 nanosphere group (15.09 +/- 4.81 days) and the other three groups [PBS (7.90 +/- 1.20, t = -4.594, P < 0.001), PLGA (8.44 +/- 0.88, t = - 4.074, P = 0.001) and dexamethasone (10.44 +/- 1.42, t = -2.790, P = 0.012)]. The rejected corneas in the FK506 nanosphere group showed significantly fewer CD4, CD8, CD68, CD79, vascular endothelial growth factor, ICAM, and tumor growth factor-beta(1)-positive cells than those in the other groups.
FK506 0.01% nanospheric-suspension eye drops delayed the occurrence of corneal allograft rejection and prolonged allograft survival time. The FK506 nanospheres may be valuable in suppressing corneal graft rejection.
Available from: Bernardo Kaplan Moscovici
- "Tacrolimus is a macrolide with immunomodulatory action that was isolated from Streptomyces tsukubaensis fermentation and becomes biologically active only when it binds to immunophilin. Tacrolimus (FK506) inhibits calcium-dependent events, such as interleukin-2 gene transcription , nitric oxide synthase activation, cell degranulation, and apoptosis       . Generally, tacrolimus suppresses the immune "
[Show abstract] [Hide abstract]
ABSTRACT: To describe the clinical efficacy of the treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop.
Prospective double-blind randomized study.
Institutional outpatient clinic.
Forty-eight eyes of twenty-four patients with dry eye related to Sjögren syndrome were enrolled in this study. The patients were randomized in 2 groups: tacrolimus (n=14) and vehicle (n=10) group.
The tacrolimus group received a vial containing tacrolimus 0.03% (almond oil as vehicle) and the other group received the almond oil vehicle. All patients were instructed to use the eye drops every 12h in the lower conjunctival sac.
Schirmer I test, break-up-time (BUT), corneal fluorescein and Rose Bengal staining scores were evaluated in all patients one day before the treatment (baseline), 7, 14, 28 and 90 days after treatment with the eye drops.
The average fluorescein and Rose Bengal scores improved statistically after 7 days of treatment and even more after 90 days. The average Schirmer I and BUT values were unchanged after 7, 14 and 21 days but did show an improvement relative to baseline after 28 days of treatment. Schirmer I, BUT, fluorescein and Rose Bengal did not show any statistical significance in the vehicle group.
Topical 0.03% tacrolimus eye drop improved tear stability and ocular surface status in cases of inflammatory or SS-related dry eye.
ClinicalTrials.gov Identifier: NCT01850979.
Copyright © 2015 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.
Contact lens & anterior eye: the journal of the British Contact Lens Association 05/2015; 38(5). DOI:10.1016/j.clae.2015.04.004 · 1.37 Impact Factor
Available from: Xiaolei Li
- "In the current study, we investigated the immunosuppressive effect of FK506 on preventing the development of epidural scar adhesion. The concentration of FK506 chosen was based on previous research (Fei et al., 2008; Arslan et al., 2012). Multiple parameters including the Rydell classification, the hydroxyproline content, the histological analysis, the number of fibroblasts and the mRNA measurement were used to evaluate the effect of FK506 on preventing epidural adhesion after laminectomy. "
[Show abstract] [Hide abstract]
ABSTRACT: There was no previous study about topical application of tacrolimus (FK506) could inhibit fibroblast proliferation and prevent epidural scar adhesion after laminectomy. We intended to illustrate the effect of FK506 on inhibiting fibroblast proliferation and preventing epidural scar adhesion after laminectomy in rat model. In our study, seventy-two rats were randomly divided into four groups (0.1mg/ml group, 0.05mg/ml group, 0.01mg/ml group and control group). Laminectomy was performed at Lumbar-1 level, and then different concentrations of FK506 and saline were applied to the laminectomy sites. Four weeks later the rats were killed and the epidural adhesion was evaluated. Macroscopic assessment, hydroxyproline content analysis, histological analysis and mRNA measurements were used to evaluate the effect of FK506 on reducing epidural scar adhesion. The results showed that FK506 could prevent epidural scar adhesion in a dose-dependent manner. Little epidural adhesions were seen in the laminectomy sites treated with 0.1mg/ml FK506. The hydroxyproline content, the number of fibroblasts, the mRNA expression level of IL-2 and TGF-β1 in 0.1mg/ml FK506 group were significantly less than those of 0.05mg/ml FK506 group, 0.01mg/ml FK506 group and control group. However, dense epidural adhesions were found in 0.01mg/ml FK506 group and control group. The hydroxyproline content and the number of fibroblasts in 0.01mg/ml group showed no significant difference compared with those of control group. In conclusion, topical application of 0.1mg/ml FK506 could inhibit fibroblast proliferation and prevent epidural scar adhesion after laminectomy in rat model.
European journal of pharmacology 12/2012; 699(1-3). DOI:10.1016/j.ejphar.2012.11.037 · 2.53 Impact Factor
[Show abstract] [Hide abstract]
Immunologic rejection is the main cause of corneal graft failure.
Acute rejection is mainly mediated by T cells, and can be prevented with steroids, IL-2 inhibitors (cyclosporine, tacrolimus),
mycopheno-late mofetil, and TOR-inhibitors (everolimus, rapamycin).
Based on their risk of immunologic rejection, corneal transplants are rated as either normal-risk or high-risk transplants.
In a normal-risk situation, the postoperative application of topical steroids accompanied by a short course of systemic steroids
is sufficient to prevent acute graft rejection in most cases.
In high-risk keratoplasty, systemic immunosuppression with mycophenolate mofetil or cyclosporine has to be used to maintain
clear graft survival.
Topical immunosuppression with either cyclosporine A or tacrolimus might present an attractive therapeutic approach to reduce
drug-specific systemic side effects.
More specific approaches using monoclonal antibodies, which target only selected aspects of the host's immune response, have
failed to safely and sufficiently prolong graft survival in experimental settings, and have therefore not gained clinical
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.